Table 1.
Clinicopathologic characteristics of patients in PVC group and control group before and after propensity score matching
| Variable | Before propensity score matching | After propensity score matching | ||||
|---|---|---|---|---|---|---|
| PVC | Control | P value | PVC | Control | P value | |
| Sex | .652a | .561a | ||||
| Female | 5 (7.5%) | 33 (9.9%) | 5 (7.5%) | 8 (11.9%) | ||
| Male | 62 (92.5%) | 301 (90.1%) | 62 (92.5%) | 59 (88.1%) | ||
| Age (y) | .033 | .861 | ||||
| ≤50 | 39 (58.2%) | 147 (44.0%) | 39 (58.2%) | 40 (59.7%) | ||
| >50 | 28 (41.8%) | 187 (56.0%) | 28 (41.8%) | 27 (40.3%) | ||
| Degree of PVTT | <.001 a | .706 | ||||
| Type Ⅰ‐Ⅱ | 46(68.7%) | 302 (90.4%) | 46 (68.7%) | 48 (71.6%) | ||
| Type Ⅲ | 21 (31.3%) | 32 (9.6%) | 21 (31.3%) | 19 (28.4%) | ||
| Edmondson stage | .663 | .213 | ||||
| Ⅰ‐Ⅱ | 29 (43.3%) | 135 (40.4%) | 29 (43.3%) | 22 (32.8%) | ||
| Ⅲ‐Ⅳ | 38 (56.7%) | 199 (59.6%) | 38 (56.7%) | 45 (67.2%) | ||
| Tumor number | .704 | .117 | ||||
| Single | 34 (50.7%) | 161 (48.2%) | 34 (50.7%) | 25 (37.3%) | ||
| Multiple | 33 (49.3%) | 173 (51.8%) | 33 (49.3%) | 42 (62.7%) | ||
| Tumor encapsulation | .851a | .585a | ||||
| None | 58 (86.6%) | 284 (85.0%) | 58 (86.6%) | 61 (91.0%) | ||
| Complete | 9 (13.4%) | 50 (15.0%) | 9 (13.4%) | 6 (9.0%) | ||
| Tumor size(cm) | .015 | 1.000 | ||||
| ≤5 | 10 (14.9%) | 98 (29.3%) | 10 (14.9%) | 10 (14.9%) | ||
| >5 | 57 (85.1%) | 236 (70.7%) | 57 (85.1%) | 57 (85.1%) | ||
| AFP(ng/mL) | .908 | .484 | ||||
| ≤400 | 30 (44.8%) | 147 (44.0%) | 30 (44.8%) | 26 (38.8%) | ||
| >400 | 37 (55.2%) | 187 (56.0%) | 37 (55.2%) | 41 (61.2%) | ||
| Anti‐HCV | 1.000 | .511 | ||||
| Negative | 63 (94.0%) | 313 (93.7%) | 61 (91.0%) | 63 (94.0%) | ||
| Positive | 4 (6.0%) | 21 (6.3%) | 6 (9.0%) | 4 (6.0%) | ||
| HBsAg | .688a | .791a | ||||
| Negative | 7 (10.4%) | 43 (12.9%) | 7 (10.4%) | 9 (13.4%) | ||
| Positive | 60 (89.6%) | 291 (87.1%) | 60 (89.6%) | 58 (86.6%) | ||
| HBV DNA (IU/mL) | .873 | .579 | ||||
| ≤104 | 47 (70.1%) | 231 (69.2%) | 47 (70.1%) | 44 (65.7%) | ||
| >104 | 20 (29.9%) | 103 (30.8%) | 20 (29.9%) | 23 (34.3%) | ||
| ALT(U/L) | .029 | .812 | ||||
| ≤75 | 56 (83.6%) | 310 (92.8%) | 56 (61.2%) | 57 (59.7%) | ||
| >75 | 11 (16.4%) | 24 (7.2%) | 11 (38.8%) | 10 (40.3%) | ||
| GGT(U/L) | .205 | .476 | ||||
| ≤54 | 12 (17.9%) | 84 (25.1%) | 12 (17.9%) | 9 (28.4%) | ||
| >54 | 55 (82.1%) | 250 (74.9%) | 55 (82.1%) | 58 (71.6%) | ||
| Albumin (g/dL) | .419 | .511 | ||||
| ≤3.5 | 4 (6.0%) | 30(9.0%) | 6 (9.0%) | 4 (6.0%) | ||
| >3.5 | 63 (94.0%) | 304 (91.0%) | 61 (91.0%) | 63 (94.0%) | ||
| PLT (×109/L) | .743 | 1.000 | ||||
| ≤100 | 14 (20.9%) | 64 (19.2%) | 14 (20.9%) | 14 (20.9%) | ||
| >100 | 53 (79.1%) | 270 (80.8%) | 53 (79.1%) | 53 (79.1%) | ||
| PT(s) | .252 | .612 | ||||
| ≤13 | 59 (88.1%) | 275 (82.3%) | 59 (88.1%) | 57 (88.1%) | ||
| >13 | 8(11.9%) | 59 (17.7%) | 8 (14.9%) | 10 (11.9%) | ||
| Liver cirrhosis | .984 | .861 | ||||
| No | 29 (43.3%) | 145 (43.4%) | 29 (43.3%) | 28 (41.8%) | ||
| Yes | 38 (56.7%) | 189 (56.6%) | 38 (56.7%) | 39 (58.2%) | ||
| Child–Pugh class | .781a | .718 | ||||
| A | 64 (95.5%) | 312 (93.4%) | 64 (95.5%) | 62 (92.5%) | ||
| B | 3 (4.5%) | 22 (6.6%) | 3 (4.5%) | 5 (7.5%) | ||
Significant P‐values are shown in bold.
Abbreviations: AFP, alpha‐fetoprotein; ALT, alanine aminotransferase; GGT, gamma glutamyl transpeptidase; HBsAg, hepatitis B surface antigen; PLT, platelet count; PVC, portal vein chemotherapy; PVTT, portal vein tumor thrombosis.
a
Fisher's exact test.